Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Caroline Hartley, a Senior Postdoctoral Research Fellow in the Paediatric Neuroimaging Group, has been awarded the highly competitive Sir Henry Dale Fellowship.

Feet of new born baby under ultraviolet lamp in the incubator

The scheme is a partnership between the Royal Society and the Wellcome Trust, and provides five years of funding for postdoctoral researchers who aim to become independent scientists leading their own groups. Dr Hartley’s research programme is focused on understanding the relationship between apnoeas and brain function in premature infants; it is due to start in 2019.


Premature infants often experience apnoeas – cessation of breathing – which can result in decreased oxygen supply to the brain. Yet whether this impacts brain development is unclear. The aim of Caroline's Fellowship is to gain a better understanding of the interaction between brain activity and apnoeas in premature infants in both the immediate and long-term, with the ultimate aim of improving outcomes for prematurely-born children.


I am truly honoured to be awarded this Fellowship and very excited to have the opportunity to investigate these fascinating and clinically relevant questions. Current rapid advances in technology will allow me to harness new developments and derive novel tools to obtain a comprehensive picture of preterm development, which I hope will lead to improved treatment for some of the most vulnerable members of our society" - said Dr Hartley.














Professor Rebeccah Slater, the head of the Paediatric Neuroimaging Group, commented on the Fellowship: "Caroline's award of a Sir Henry Dale Fellowship is a fantastic personal achievement. Supporting postdocs making the transition to establishing their independent academic careers is one of the most rewarding aspects of my job, and I am delighted that Caroline will remain in our department to further build paediatric neuroscience research at Oxford."

The Department of Paediatrics' ongoing commitment to support early careers researchers has recently been recognised with an Athena SWAN Silver Award. "This fellowship is in recognition of  Caroline’s outstanding scientific contributions at this early stage of what is without a doubt a promising career. In the name of the entire Department of Paediatrics, I wish her the very best" said Professor Georg Hollander, the Head of Department.

Read more about the research of the Paediatric Neuroimaging Group.

Similar stories

Irene Roberts delivers Ham-Wasserman Lecture

Presented at the American Society of Hematology Annual Meeting, the award and lectureship recognises individuals from outside the United States who have made significant contributions to Haematology.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Oxford scientist named Australian of the Year in the UK

The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.